# Cancer Drug References: Papers & Clinical Evidence

## Key Clinical Trials and Citations

### EGFR Inhibitors
- **Osimertinib**  
  ðŸ“„ **FLAURA Phase III Trial**  
  - *Mok TS, et al. N Engl J Med. 2017;376(7):629-640.*  
  - Demonstrated PFS advantage over 1st-gen EGFR TKIs in T790M+ NSCLC  

- **Erlotinib**  
  ðŸ“„ **BR.21 Trial**  
  - *Shepherd FA, et al. N Engl J Med. 2005;353(2):123-132.*  
  - First EGFR TKI to show survival benefit in advanced NSCLC  

### PARP Inhibitors
- **Olaparib**  
  ðŸ“„ **OlympiAD Trial**  
  - *Robson M, et al. N Engl J Med. 2017;377(6):523-533.*  
  - PFS improvement in BRCA-mutated breast cancer  

  ðŸ“„ **PROfound Trial**  
  - *de Bono J, et al. N Engl J Med. 2020;382(22):2091-2102.*  
  - First PARPi approved for prostate cancer  

### BRAF/MEK Inhibitors
- **Dabrafenib + Trametinib**  
  ðŸ“„ **COMBI-d Trial**  
  - *Robert C, et al. Lancet. 2015;386(9992):444-451.*  
  - Superior to monotherapy in BRAF V600E melanoma  

### Immune Checkpoint Inhibitors
- **Pembrolizumab**  
  ðŸ“„ **KEYNOTE-001**  
  - *Garon EB, et al. N Engl J Med. 2015;372(21):2018-2028.*  
  - Foundation for PD-1 blockade in NSCLC  

- **Nivolumab**  
  ðŸ“„ **CheckMate-067**  
  - *Wolchok JD, et al. N Engl J Med. 2017;377(14):1345-1356.*  
  - Long-term survival in melanoma  

### BCR-ABL Inhibitors
- **Imatinib**  
  ðŸ“„ **IRIS Trial**  
  - *Druker BJ, et al. N Engl J Med. 2006;355(23):2408-2417.*  
  - Established TKI standard for CML  

## Mechanistic Studies
- **MET Inhibitors (Capmatinib/Tepotinib)**  
  ðŸ“„ *Paik PK, et al. N Engl J Med. 2020;383(10):931-943.*  
  - GEOMETRY mono-1 trial for METex14 skipping NSCLC  

- **RET Inhibitors (Selpercatinib)**  
  ðŸ“„ *Drilon A, et al. N Engl J Med. 2020;383(9):813-824.*  
  - LIBRETTO-001 trial demonstrating RET fusion activity  

## Review Articles
- ðŸ“„ *Zehir A, et al. Nat Med. 2017;23(6):703-713.*  
  "Mutational landscape of metastatic cancers"  
  - Foundation for precision oncology approaches  

- ðŸ“„ *Hyman DM, et al. Nature. 2017;548(7667):297-303.*  
  "Precision medicine for cancers with targetable alterations"  

## Important Guidelines
- ðŸ“„ *NCCN Guidelines v3.2024* - Drug selection algorithms  
- ðŸ“„ *ESMO Clinical Practice Guidelines* - Biomarker testing recommendations  

---
*Last updated: July 2025*  
*Data sources: PubMed, ClinicalTrials.gov, FDA labels*